In this study, we further evaluated these underexplored constituents as potential therapeutic candidates for neurodegenerative disease, with particular emphasis on the tau aggregation inhibitory activity of the diarylheptanoid (3R,5R)-octahydrocurcumin. Here, MAPT is linked to neurodegenerative disease.